HolderBook

INTERNATIONAL BIOTECHNOLOGY TRUST PLC

Reported holdings as of Q3 2023, from 20 quarterly filings.

This filer last reported in Q3 2023; the most recent quarter on file across all filers is Q2 2026. Firms that restructure stop filing under one CIK and start under another, so a successor entity may hold these positions now under a similar name.

CIK
942257
Reported value
$296.8M
Positions
65
Top 10 weight
47.8%
Filed
2023-11-14
Days after quarter end
45

Holdings

SecurityTickerValue SharesWeightWeight change Held Change
AMGEN INCAMGN$21.3M79,2467.17%-0.75pp20q-32.4%-$10.2M
INCYTE CORPINCY$20.7M358,4546.97%+0.19pp20qHELD
GILEAD SCIENCES INCGILD$17.5M233,5845.90%+2.51pp20q+61.6%+$6.7M
INTRA-CELLULAR THERAPIES INCITCI$16.5M317,8565.57%+2.17pp15q+79.7%+$7.3M
BIOMARIN PHARMACEUTICAL INCBMRN$13.6M153,6564.58%+3.03pp20q+162.0%+$8.4M
SUPERNUS PHARMACEUTICALSSUPN$11.8M426,5003.96%-0.83pp10q-18.5%-$2.7M
VERA THERAPEUTICS INCVERA$10.4M758,3553.50%-1.26pp8q-22.2%-$3.0M
BIOGEN INCBIIB$10.3M40,2003.48%+2.53pp6q+265.5%+$7.5M
HARMONY BIOSCIENCES HLDGS INHRMY$10.3M314,5003.47%-2.64pp10q-44.9%-$8.4M
MIRATI THERAPEUTICS INCMRTX$9.4M216,0003.17%+0.31pp19q-16.9%-$1.9M
ULTRAGENYX PHARMACEUTICAL INRARE$8.9M250,0523.00%+1.88pp11q+212.4%+$6.1M
UNIQURE NVQURE$8.3M1,241,5002.81%+2.75pp18q+7909.7%+$8.2M
AURINIA PHARMACEUTICALS INCAUPH$8.1M1,040,5302.72%+1.03pp13q+81.4%+$3.6M
UNITED THERAPEUTICS CORP DELUTHR$7.7M33,9592.58%-0.97pp7q-35.6%-$4.2M
VERTEX PHARMACEUTICALS INCVRTX$7.3M21,0002.46%+0.21pp3qHELD
REGENERON PHARMACEUTICALSREGN$7.3M8,8472.45%-3.45pp14q-67.2%-$14.9M
ILLUMINA INCILMN$6.9M50,5002.34%-0.55pp9qHELD
ALNYLAM PHARMACEUTICALS INCALNY$6.5M36,8002.20%-2.52pp20q-54.9%-$7.9M
AMYLYX PHARMACEUTICALS INCAMLX$5.4M295,0001.82%+1.65pp2q+1080.0%+$4.9M
KRYSTAL BIOTECH INCKRYS$5.3M46,0921.80%+0.16pp8qHELD
KARUNA THERAPEUTICS INCKRTX$5.2M30,5001.74%+0.04pp3q+18.7%+$811.6K
AXSOME THERAPEUTICS INCAXSM$4.1M58,3001.37%+0.10pp2qHELD
ERASCA INCERAS$3.8M1,926,0001.28%+0.08pp3q+35.1%+$985.0K
ACADIA PHARMACEUTICALS INCACAD$3.7M179,7021.26%+0.16pp4q+19.0%+$597.3K
REVANCE THERAPEUTICS INCRVNC$3.3M288,7261.11%-1.11pp5qHELD
NEUROCRINE BIOSCIENCES INCNBIX$3.2M28,8771.09%-0.88pp2q-58.1%-$4.5M
SAREPTA THERAPEUTICS INCSRPT$3.2M26,7001.09%+0.43pp2q+42.0%+$957.2K
ROCKET PHARMACEUTICALS INCRCKT$3.2M156,0001.08%+0.13pp9qHELD
DENALI THERAPEUTICS INCDNLI$3.2M154,0001.07%-0.62pp8q-18.1%-$700.4K
ASTRAZENECA PLCAZN$3.1M46,5001.06%-newNEW
XENON PHARMACEUTICALS INCXENE$3.1M91,5001.05%+0.75pp10q+258.8%+$2.3M
CRISPR THERAPEUTICS AGCRSP$2.9M63,0000.96%-newNEW
MADRIGAL PHARMACEUTICALS INCMDGL$2.7M18,3000.90%-0.39pp2qHELD
LEGEND BIOTECH CORPLEGN$2.6M38,0000.86%+0.06pp9qHELD
HALOZYME THERAPEUTICS INCHALO$2.4M62,2000.80%-0.25pp3q-34.9%-$1.3M
MARINUS PHARMACEUTICALS INCMRNS$2.3M290,0000.79%+0.49pp2q+222.2%+$1.6M
BEONE MEDICINES LTDONC$2.3M12,7000.77%+0.30pp8q+46.0%+$718.6K
JAZZ PHARMACEUTICALS PLCJAZZ$2.2M17,2000.75%+0.10pp10qHELD
MIRUM PHARMACEUTICALS INCMIRM$2.1M67,5000.72%+0.19pp5qHELD
IOVANCE BIOTHERAPEUTICS INCIOVA$2.0M445,0000.68%+0.54pp13q+584.6%+$1.7M
IONIS PHARMACEUTICALS INCIONS$1.9M43,0000.66%+0.12pp3qHELD
ZAI LAB LTDZLAB$1.9M78,9580.65%-0.02pp10qHELD
GENMAB A/SGMAB$1.6M44,3000.53%-newNEW
CELLDEX THERAPEUTICS INC NEWCLDX$1.3M48,0990.45%-0.05pp2qHELD
COGENT BIOSCIENCES INCCOGT$1.3M135,0000.44%-newNEW
DYNE THERAPEUTICS INCDYN$1.2M137,7510.41%-0.62pp11q-54.2%-$1.5M
NOVOCURE LTDNVCR$1.2M74,0000.40%flat6q+131.2%+$677.5K
AMICUS THERAPEUTICS INCFOLD$1.1M90,0000.37%-newNEW
CYTOKINETICS INCCYTK$1.1M37,0000.37%flat2qHELD
GUARDANT HEALTH INCGH$1.1M36,5000.36%-0.03pp10qHELD
INSMED INCINSM$1.0M40,1000.34%+0.08pp19qHELD
BLUEPRINT MEDICINES CORPBPMC$1.0M20,0000.34%-newNEW
AKERO THERAPEUTICS INCAKRO$935.2K18,4890.32%-0.80pp2q-76.4%-$3.0M
KEZAR LIFE SCIENCES INCKZR$830.5K703,8250.28%-newNEW
INTELLIA THERAPEUTICS INCNTLA$757.9K24,0000.26%-0.04pp8qHELD
PROTHENA CORP PLCPRTA$722.9K15,0000.24%-newNEW
AGIOS PHARMACEUTICALS INCAGIO$593.5K24,0000.20%-0.01pp2qHELD
BEAM THERAPEUTICS INCBEAM$564.7K23,5000.19%-0.04pp6qHELD
VENTYX BIOSCIENCES INCVTYX$520.6K15,0000.18%+0.03pp3qHELD
VIR BIOTECHNOLOGY INCVIR$439.9K47,0000.15%-newNEW
NOVABRIDGE BIOSCIENCESNBP$409.9K310,4990.14%-0.14pp11qHELD
PTC THERAPEUTICS INCPTCT$380.6K17,0000.13%-0.08pp19qHELD
ARVINAS INCARVN$333.5K17,0000.11%-0.02pp5qHELD
PROTAGONIST THERAPEUTICS INCPTGX$331.9K19,9000.11%-0.06pp2qHELD
RELMADA THERAPEUTICS INCRLMD$30.0K10,0000.01%flat9qHELD

By sector

Industry comes from the SIC code on each company's own SEC filings, which is self-reported and sometimes out of date. Derivative exposure is counted with the shares. Securities the SEC assigns no industry - funds, trusts, foreign issues - are shown as not classified rather than dropped.

Biotech & Pharma 85.4%Other sectors 0.8%Not classified 13.9%
 
SectorValueShare
Biotech & Pharma$253.4M85.4%
Other sectors$2.3M0.8%
Not classified$41.1M13.9%

Quarter by quarter

QuarterValuePositions NewAddedTrimmed ExitedTop 10 Days to file
Q3 2023$296.8M6591713547.8%45
Q2 2023$328.5M611317121651.5%39
Q1 2023$358.4M647177649.9%48
Q4 2022$323.8M63397651.2%32
Q3 2022$311.9M6665911848.3%39
Q2 2022$9.6M7815162747.0%47
Q1 2022$443.4M70812201147.3%50
Q4 2021$448.9M73131810846.7%46
Q3 2021$414.6M6810229852.3%43
Q2 2021$378.8M6615147554.1%42
Q1 2021$378.1M569149555.2%47
Q4 2020$366.1M525134657.0%50
Q3 2020$309.8M535127558.2%62
Q2 2020$300.8M5331110657.0%14
Q1 2020$219.4M5687201560.7%48
Q4 2019$277.6M6391911451.2%139
Q3 2019$216.4M5821315856.7%45
Q2 2019$269.7M6491915748.6%45
Q1 2019$270.7M62211412443.7%44
Q4 2018$161.1M45000056.9%45

Rows marked UNVERIFIED ID, PLACEHOLDER ID, TICKER AS ID or NON-CUSIP ID carry an identifier that is not a valid CUSIP. They are shown because the filer reported that money, but treat the security named with caution - hover the chip for what is wrong with it, and see the methodology.

Held counts consecutive filings in which this manager reported the position, and can reach further back than the quarters listed above: the tabs begin at Q4 2018 because earlier coverage is too sparse to describe a market, but tenure is counted over every filing we hold, some reaching to 2007. A position sold and later rebought starts again from one.

Weight change is the shift in this position's share of the whole book, in percentage points. It is the more useful column: when money flows into or out of a broad fund, almost every holding is bought or sold at once, so added and trimmed largely track flows. A weight that rose while the book shrank is a decision. Both compare with the previous quarter this filer reported, not the previous calendar quarter.